{
    "medicine_id": "f0e27cc5a008fc64100cd4f33719e5e147364f6a",
    "platform_id": "DB04985",
    "metadata": {
        "name": "Potiga 50 mg 1 Tablet film coated",
        "composition": "50 mg 1 Tigapotide",
        "clinical_particulars": {
            "therapeutic_indications": "For the treatment of late stage Hormone Refractory Prostate Cancer HRPC for which no effective therapy currently exists",
            "contraindications": {
                "disease": "Non clinical toxicology studies in mice and primates indicated that a treatment for 28 consecutive days by intravenous administration of PCK3145 up to 450 mg kg day in mice and 25 mg kg day in primates resulted in no clear evidence of toxicity",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "PCK3145 is a synthetic 15 mer peptide that is derived from the natural sequence of amino acids of the prostate secretory protein PSP94 one of three predominant proteins found in human seminal fluid PSP94 expression in the prostate is down regulated in patients with advanced prostate cancer and believed to be a survival mechanism for the cancer cells Results from an earlier trial conducted in the U K showed PCK3145 to be safe and well tolerated at all doses tested and further suggest that it also plays a role in preventing the metastatic process as measured by its effect on MMP 9 levels a Gelatinase B enzyme involved in angiogenesis tumor invasion and metastasis",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}